MetaCap

GH Research (GHRS) vs Ocular Therapeutix (OCUL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GH Research (GHRS) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 25.1% versus a loss of 54.5%. Over five years, OCUL leads with a -14.8% price change compared with -21.0% for GHRS. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GHRS+25.08%OCUL-54.49%
+127%+32%-63%
Nov 21, 20251 yearNov 20, 2026
GHRS-32.08%OCUL-16.74%
+127%+19%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GHRS versus OCUL key metrics
MetricGHRSOCUL
Share price$17.53$5.57
Market cap$1.20B$1.23B
1-day change-5.55%-4.95%
YTD return+38.03%-54.12%
1-year return+25.08%-54.49%
5-year return-21.00%-14.83%
EPS (TTM)$-0.94$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$51.95M
Revenue growth (YoY)—-18.47%
Net income (latest FY)$-48.26M$-265.94M
Gross margin—87.35%
Operating margin—-519.75%
Net margin—-511.90%
52-week high$31.44$16.44
52-week low$12.04$5.54
Distance from 52-week high-44.24%-66.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+144.67%+361.94%
Average volume294.69K3.03M
Shares outstanding68.68M220.02M
Employees73325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GHRS has outperformed OCUL by 79.6 percentage points over the past year.

About GH Research

GHRS stock →

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

GHRS vs OCUL FAQ

Which is bigger, GH Research or Ocular Therapeutix?

Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.20B for GH Research (GHRS).

Which stock has performed better over the past year, GHRS or OCUL?

GHRS returned +25.08% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.

Are GH Research and Ocular Therapeutix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons